Diabesity Rounds

Monthly quiz

October 2026: ten questions on the month’s reports. Finish it to get a Certificate of Participation from Diabesity Rounds.

This is a self-assessment for interest. It is not CME and carries no credit points.

1. In RCTs comparing lower with higher GDM diagnostic criteria, what happened to neonatal hypoglycaemia with the lower criteria?
2. In the ATTAIN-J trial of oral orforglipron, which group had the most participants stopping treatment because of nausea?
3. In the pooled analysis of eight GLP-1 RA trials, the ratio of hazard ratios for MACE (65 or older vs under 65) was 1.03 (95% CI 0.85-1.25). What does this show?
4. In the British Columbia cohort of adults aged 75 or older, how was acute kidney injury risk with SGLT2 inhibitors versus DPP-4 inhibitors?
5. In the CagriSema meta-analysis in type 2 diabetes, which statement about the comparison with semaglutide 2.4 mg matches the findings?
6. In the FLOW analysis by baseline eGFR, what share stopped treatment because of gastrointestinal adverse events, semaglutide versus placebo?
7. In the Swedish trial-eligible cohort of people starting insulin, how did all-cause mortality compare between degludec and glargine?
8. In the 6-month trial of Smart MDI versus MDI plus CGM in type 1 diabetes with HbA1c of 8% or more, what was the main result?
9. In the Maccabi cohort of type 1 diabetes, which sex had the larger relative excess mortality compared with matched controls?
10. An Indian single-arm study reported 60.9% estimated remission with a moderate carbohydrate diet and exercise in early type 2 diabetes. How do the authors describe the findings?